Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-221 PK and Safety in Healthy Japanese vs Caucasian Males
NCT02387866Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enasidenib in acute myeloid leukemia (AML) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Area Under the Curve from Time 0 to Last Measurable Concentration up to 3 days, Area Under the Curve from Time 0 to Infinity up to 3 days and 5 more. Started Mar 2015; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02387866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387866.